Hermetica Superfood Encyclopedia
The Short Answer
Chuchuhuasi bark contains triterpenes (celastrol, friedelin, epifriedelanol), dihydro-β-agarofuran sesquiterpenes, and alkaloids (mayteine, macrocarpines A–D) that suppress inflammatory mediators including PGE2 and nitric oxide in macrophage models. The most quantified preclinical finding is macrocarpine A exhibiting cytotoxicity against HL-60 leukemia cells at an IC50 of 1.7 µM, while 22-epi-triptotriterpenonic acid A inhibited HIV gp120-CD4 binding with an EC50 of 1 µg/mL; no human clinical trials have confirmed these effects.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordchuchuhuasi benefits
Chuchuhuasi — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
The triterpene celastrol and caffeoylbetulin derivatives suppress prostaglandin E2 (PGE2) production and nitric oxide (NO) release in LPS-stimulated RAW 264.7 macrophages; 3-(E)-caffeoylbetulin demonstrated an IC50 of 10.8 µM for PGE2 inhibition, providing mechanistic support for traditional use in arthritis and muscle pain.
**Analgesic and Muscle-Relaxant Effects**
Traditional Amazonian use centers on bark decoctions to relieve musculoskeletal pain and promote muscle relaxation; the anti-inflammatory sesquiterpene and triterpene fraction is proposed to mediate these effects, though controlled human trials have not been conducted.
**Antitumor and Cytotoxic Potential**
Novel alkaloids macrocarpines A–D isolated from roots showed selective cytotoxicity against human tumor cell lines; macrocarpine A achieved an IC50 of 1.7 µM against HL-60 promyelocytic leukemia cells through apoptosis induction, representing a significant in vitro finding.
**Antiviral Properties**
The triterpene 22-epi-triptotriterpenonic acid A demonstrated inhibition of HIV gp120-CD4 receptor interaction at an EC50 of 1 µg/mL, reducing binding efficiency by approximately 55% in cell-based assays, suggesting potential as an antiretroviral adjunct candidate.
**Antibacterial Activity**
Bark and leaf extracts exhibited antibacterial activity with IC50 values below 100 µg/mL against tested pathogenic strains, with potency described as comparable to ciprofloxacin in some assays; this supports the traditional use for infectious gastrointestinal conditions.
**Neuroprotective and Antipsychotic-Like Effects**
Epifriedelanol has demonstrated neuroprotective properties in animal models by reducing oxidative tissue damage; separate rodent studies reported antipsychotic-like behavioral changes with chuchuhuasi extracts comparable to haloperidol, suggesting central nervous system activity warranting further investigation.
**Male Reproductive Support**
Preclinical studies in male rats reported statistically significant improvements in sperm motility and reproductive organ weight (p<0.05) following bark extract administration, supporting traditional use as a libido and fertility tonic, though mechanisms and human relevance remain uncharacterized.
Origin & History
Natural habitat
Chuchuhuasi is a large canopy tree native to the Amazon rainforest basin, found primarily in Peru, Brazil, Colombia, and Ecuador, typically growing in lowland tropical forests below 1,000 meters elevation. The tree favors humid, well-drained soils along riverbanks and forest interiors, and can reach heights of 20–30 meters. Bark harvesting by indigenous communities has been documented for centuries, with the tree rarely cultivated commercially and primarily wildcrafted from old-growth Amazonian forest.
“Chuchuhuasi has been used for centuries by indigenous Amazonian peoples including Shipibo-Conibo, Quechua, and mestizo communities in Peru and neighboring countries, where the bark is regarded as one of the most important medicinal trees of the rainforest. Traditional healers (curanderos) prescribe bark decoctions and tinctures for rheumatism, back pain, muscle inflammation, sexual debility, menstrual irregularity, and antiparasitic purposes, with the name 'chuchuhuasi' reportedly deriving from Quechua words meaning 'trembling back' in reference to its analgesic use. Scientific interest in the alkaloid chemistry of Maytenus species dates to the 1960s when maytansine—a potent antimitotic agent—was isolated from related species, spurring investigation of macrocarpa for antitumor compounds. The tree occupies a prominent position in Amazonian plant medicine comparable to cat's claw (Uncaria tomentosa) and has been featured in ethnobotanical surveys cataloguing Peruvian medicinal flora since at least the 1970s.”Traditional Medicine
Scientific Research
The existing evidence base for Chuchuhuasi consists entirely of in vitro cell culture studies and animal model experiments; no peer-reviewed human clinical trials have been published as of the available literature. In vitro studies have yielded quantified IC50 and EC50 values for isolated compounds—notably macrocarpine A (IC50 1.7 µM vs. HL-60 cells) and 22-epi-triptotriterpenonic acid A (EC50 1 µg/mL for HIV gp120 inhibition)—providing meaningful mechanistic data but no pharmacokinetic or safety translation to humans. Rodent studies have reported statistically significant effects on sperm motility (p<0.05) and antipsychotic-like behavior comparable to haloperidol, though sample sizes, strain details, and effect sizes are incompletely reported in available sources. The overall evidence quality is preliminary, with a critical absence of pharmacokinetic studies, dose-escalation trials, or Phase I safety data in humans, representing a substantial gap between ethnobotanical use and evidence-based clinical application.
Preparation & Dosage
Traditional preparation
**Bark Decoction (Traditional)**
10–15 g dried bark in 500 mL water for 20–30 minutes; consume 1 cup (approximately 150–250 mL) 2–3 times daily; the most historically documented form used by Amazonian indigenous communities
Simmer .
**Alcohol Tincture**
3–5 mL of a standardized 1:5 bark tincture (typically 40–60% ethanol) taken 2–3 times daily; alcohol extraction favors lipophilic sesquiterpenes and triterpenes with limited water solubility
**Dried Bark Capsules/Powder**
000 mg per capsule, 1–3 times daily; no standardization to specific active markers is currently established for commercial products
Commercially available as encapsulated bark powder; typical dosing ranges from 500–1,.
**Standardized Extracts**
Research-grade alcohol extracts have been used in preclinical studies; no standardization percentage for celastrol, mayteine, or macrocarpines has been established for commercial supplements.
**Timing Note**
Traditional use favors consumption before meals for digestive and anti-inflammatory effects; no pharmacokinetic data exists to guide timing optimization.
**Bioavailability Consideration**
The lipophilic nature of macrocarpines and related sesquiterpenes limits aqueous extraction efficiency; alcohol-based preparations or oil-soluble formulations may deliver higher active compound concentrations than water decoctions alone.
Nutritional Profile
Chuchuhuasi bark is not consumed as a dietary staple and does not contribute meaningfully to macronutrient intake; its nutritional relevance lies entirely in its phytochemical composition. Key identified phytochemicals include pentacyclic triterpenes (celastrol, friedelin, epifriedelanol, maniladiol), dihydro-β-agarofuran sesquiterpene polyesters, β-carboline and macrocarpine alkaloids (macrocarpines A–D, mayteine, maytansine in trace quantities), phenolic acids (macrocarpoic acid A and B, maytenfolic acid), proanthocyanidins, and caffeoylbetulin derivatives. Specific percentage concentrations of these constituents in raw bark have not been published in available quantitative phytochemical analyses. Bioavailability of lipophilic triterpenes and sesquiterpenes from aqueous decoctions is expected to be low; alcohol-based extraction substantially improves yield of these compounds, while proanthocyanidins are more readily extracted by water.
How It Works
Mechanism of Action
Celastrol and related pentacyclic triterpenes inhibit NF-κB signaling and suppress the production of pro-inflammatory mediators including cyclooxygenase-derived PGE2 and inducible nitric oxide synthase (iNOS)-derived NO in activated macrophages, directly underpinning the anti-inflammatory profile. Dihydro-β-agarofuran sesquiterpenes such as 6β,8β,15-triacetoxy-1α,9α-dibenzoyloxy-4β-hydroxy-β-dihydroagarofuran interact with multidrug resistance P-glycoprotein and may modulate membrane transport, contributing to both cytotoxic and immunomodulatory effects. Macrocarpine alkaloids induce apoptotic cell death in tumor lines via mitochondrial pathway disruption, while the triterpene 22-epi-triptotriterpenonic acid A sterically blocks the gp120 envelope protein from engaging the CD4 receptor on T lymphocytes, interrupting HIV cellular entry. Epifriedelanol reduces oxidative stress markers in neural tissue, likely through free radical scavenging and possible modulation of dopaminergic receptor pathways, as inferred from behavioral antipsychotic equivalence studies in mice.
Clinical Evidence
No human clinical trials investigating Chuchuhuasi or its isolated constituents for any indication have been identified in the available scientific literature. The clinical rationale for its traditional use in arthritis, muscle pain, and immune support is supported only by mechanistic in vitro data and rodent behavioral studies, which cannot reliably predict therapeutic dose, efficacy magnitude, or safety in humans. Preclinical outcomes—such as macrophage PGE2 suppression and tumor cell cytotoxicity—are biologically plausible but have not been translated into measurable human endpoints such as pain scores, inflammatory biomarkers, or quality of life measures. Confidence in any therapeutic recommendation is therefore very low, and the ingredient should be considered investigational until well-designed human trials are completed.
Safety & Interactions
Formal toxicological studies in humans are absent, and the safety profile of Chuchuhuasi is extrapolated only from centuries of traditional use and limited preclinical data; no maximum tolerated dose, LD50 in humans, or clinical adverse event profile has been established. The presence of maytansine—a potent microtubule inhibitor with a narrow therapeutic index studied in oncology—in trace quantities raises theoretical cytotoxicity concerns at high doses, though quantities in bark preparations are considered pharmacologically insignificant based on available analyses. Antipsychotic-like central nervous system effects observed in rodent models suggest potential interactions with dopaminergic drugs (antipsychotics, dopamine agonists for Parkinson's disease) and warrant caution in patients on CNS-active medications. Chuchuhuasi is not recommended during pregnancy or lactation due to demonstrated in vitro cytotoxicity, lack of safety data, and traditional use as a uterine stimulant in some ethnobotanical records; individuals with liver disease or on anticoagulant therapy should also avoid use pending formal interaction studies.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Maytenus macrocarpaChuchuhuashaChuchu huasiMaytenus krukoviiCorteza de chuchuhuasi
Frequently Asked Questions
What is chuchuhuasi used for traditionally?
Chuchuhuasi bark has been used by Amazonian indigenous peoples for centuries to relieve arthritis, back pain, muscle inflammation, and menstrual irregularities, and as an antiparasitic and libido tonic. Curanderos prepare it primarily as a bark decoction (boiled in water) or tincture macerated in alcohol, with dosing typically 1 cup of decoction or 3–5 mL of tincture taken 2–3 times daily. Its traditional reputation as one of the Amazon's most important medicinal trees reflects its broad ethnobotanical applications across Peru, Brazil, and Colombia.
Does chuchuhuasi have scientific evidence supporting its benefits?
Current evidence is limited to in vitro cell studies and animal experiments; no human clinical trials have been published. Key preclinical findings include macrocarpine A achieving an IC50 of 1.7 µM against HL-60 leukemia cells and celastrol-type triterpenes suppressing PGE2 and nitric oxide in macrophage models, providing mechanistic plausibility for anti-inflammatory claims. However, without human pharmacokinetic data or randomized controlled trials, these findings cannot be directly translated into clinical recommendations.
What are the active compounds in chuchuhuasi bark?
The principal bioactive compounds identified in Maytenus macrocarpa bark and roots include pentacyclic triterpenes (celastrol, friedelin, epifriedelanol, maniladiol), dihydro-β-agarofuran sesquiterpene polyesters, and alkaloids including mayteine, maytansine (in trace amounts), and macrocarpines A–D. Phenolic acids such as macrocarpoic acid A and B, maytenfolic acid, and proanthocyanidins have also been characterized. The sesquiterpene and triterpene fractions are considered the primary drivers of anti-inflammatory and cytotoxic activity based on in vitro bioassay-guided fractionation studies.
Is chuchuhuasi safe to take, and are there any drug interactions?
Formal human safety studies do not exist, so the risk profile is based on traditional use history and limited preclinical data only. Rodent studies showing antipsychotic-like central nervous system effects suggest potential interactions with dopaminergic medications, including antipsychotics and Parkinson's medications, and caution is warranted in patients on CNS-active drugs. Chuchuhuasi is not recommended during pregnancy or breastfeeding due to in vitro cytotoxicity data and traditional records of uterine-stimulating properties.
What is the recommended dose of chuchuhuasi?
Traditional dosing guidelines, which are not supported by clinical pharmacokinetic studies, recommend bark decoction at 1 cup (150–250 mL) consumed 2–3 times daily, or alcohol tincture at 3–5 mL taken 2–3 times daily. Commercial capsule products typically contain 500–1,000 mg of dried bark powder per dose; no standardization to a specific active marker has been established for the supplement industry. Because no human dose-finding trials exist, these ranges reflect historical practice rather than evidence-based clinical dosing.
How does chuchuhuasi compare to other anti-inflammatory herbs like turmeric or boswellia?
Chuchuhuasi's anti-inflammatory mechanism centers on suppressing prostaglandin E2 (PGE2) and nitric oxide through triterpenes like celastrol, whereas turmeric primarily targets NF-κB pathways and boswellia inhibits leukotriene synthesis. While chuchuhuasi has strong traditional use for arthritis and muscle pain in Peruvian medicine, turmeric and boswellia have more extensive clinical trial data in Western populations. The choice depends on individual response and whether you're targeting PGE2-mediated inflammation specifically versus broader inflammatory pathways.
What form of chuchuhuasi extract is most bioavailable—bark powder, liquid tincture, or standardized extract?
Standardized extracts targeting caffeoylbetulin and celastrol content are theoretically more bioavailable since these active compounds are concentrated and in forms optimized for absorption. Liquid tinctures offer faster absorption than whole bark powder, though traditional preparations often use decoctions of the bark to extract both polar and non-polar compounds. Research specifically measuring chuchuhuasi bioavailability across forms is limited, so standardized extracts with documented triterpene content provide the most consistent dosing for the compounds shown to have anti-inflammatory activity.
Who is chuchuhuasi most beneficial for—people with arthritis, muscle pain, or general inflammation?
Chuchuhuasi appears most beneficial for individuals with arthritis and chronic muscle pain, given its traditional Amazonian use and in vitro evidence showing PGE2 and NO inhibition at physiologically relevant concentrations (IC50 10.8 µM). Those experiencing inflammatory conditions driven primarily by prostaglandin pathways may see greater benefit than those with other inflammatory mechanisms. However, clinical trials in humans are limited, so current use remains largely based on traditional practice and mechanistic research rather than large-scale patient outcome studies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chuchuhuasi-maytenus-macrocarpa curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
